It’s time to enter the race for increased EU competitiveness!

In his report, titled “Much More Than a Market” which was published in April, Enrico Letta states that “competitiveness means…

This is the last call for a competitive pharma industry in Europe

In two weeks, on March 19th, the environmental, public health and food safety (ENVI) committee of the European Parliament will…

Servier’s position on adherence to treatment

Over one-quarter of the EU working age population has a chronic disease, with 36% of EU adults over 65 years…

Pharmaceutical reform: adopt a holistic approach to the pharma industry

On April 26th, the European Commission released its long-awaited review of the rules framing the pharmaceutical legislation. While highly anticipated,…

Rare diseases: We need to accelerate and support the therapeutic development to better address patients’ needs.

At Servier, we strive to develop medicines for the patients who need them. Putting patients first in our daily work…

Servier European Affairs

Our contribution to the evolution of the European health
ecosystem for the benefits of patients and society

What we do:

As a company with a strong footprint in Europe, Servier strongly believes in engaging with stakeholders at all levels. This enables us to strengthen our ability to anticipate, take part in the evolution of our environment and improve health and quality of life for patients.

To this end, the European Public Affairs department is set up in Brussels, it collaborates with all stakeholders at European level with an overarching objective of accompanying the evolution of the health ecosystem for the benefits of patients and society.

Don’t hesitate to get in touch with us here!

173 233

jobs

are supported by the 10 Servier Group European subsidiaries’ activity worldwide

x9

for every direct job at one of Servier’s European subsidiary, 8 additional jobs are supported worldwide

6.3 Bn€

of GDP

are supported by the 10 Servier Group European subsidiaries’ activity worldwide

x3.4

for one euro of added value generated by one of Servier’s European subsidiary, 2.4 additional euros are generated worldwide

based on the local footprint study made by Utopies in 2018, which included 10 European subsidiaries, Biogaran and EGIS

Servier Commitments

Servier’s mission is to provide future generations with a healthier world and we work towards our purpose with passion and determination. First and foremost, as a leading pharmaceutical company, our conviction embodies patient-centricity, as well as our code of ethics and compliance, our corporate social responsibility policy, and our endowment fund. Moreover, we believe it is fundamental to nurture individual and collective commitment by giving our employees a fulfilling and rewarding work environment conducive to creativity and innovation. If you would like to know more about our commitments please click here.

12

Servier Research Centers
in 10 countries

06

Servier Production sites
across 5 countries

8,2k

Servier has almost 8 200 employees and a turnover of about €1 600 000 across Europe, UK, Switzerland, Turkey and Russia

4,2k

EGIS (a a member of the Servier Group) has 8 subsidiaries, around 4240 employees and a turnover of around €468 000 across Europe, Russia, UK , Switzerland and Turkey

230

Biogaran (which represents the generic industry in France) has 1 HQ and around 230 employees with a turnover of almost €873 740

Servier’s presence in Europe and neighbouring countries

Servier’s presence in Europe

and neighbouring countries

5

Servier Research Centers
in 3 countries (France, Denmark and Hungary)

10

Servier Production sites
across 5 countries

9

International Centers for Therapeutic Research (ICTR) for conducting clinical trials across Europe

2

Generic entities within the Servier Group: Biogaran, leader in France, and EGIS operating in Hungary and Eastern Europe

2.8

over 13,800 employees and a turnover of approximately €2.8 Bn across Europe, UK, Switzerland, Turkey and Russia